Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

pembrolizumab 2nilotinib 2avapritinib 2trastuzumab deruxtecan 1talquetamab 1pomalidomide 1montelukast 1lazertinib 1larotrectinib 1ivosidenib 1entrectinib 1dostarlimab 1daratumumab 1carfilzomib 1asciminib 1amivantamab 1Thalidomide 1TIC10 compound 1Prednisone 1Pemetrexed 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1Diphenhydramine 1Dexamethasone 1Dasatinib 1Crizotinib 1Carboplatin 1Bortezomib 1Appointments and Schedules 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Has announcements × talquetamab × Clear all
NCT03399799 2026-05-08

MonumenTAL-1

Janssen Research & Development, LLC

Phase 1 Active not recruiting
279 enrolled 1 FDA
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡